Emerging oligonucleotide therapeutics for rare neuromuscular diseases
Research and drug development concerning rare diseases are at the cutting edge of scientific technology. To date, over 7,000 rare diseases have been identified. Despite their individual rarity, 1 in 10 individuals worldwide is affected by a rare condition. For the majority of these diseases, there i...
المؤلفون الرئيسيون: | Aoki, Y, Wood, MJA |
---|---|
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
IOS Press
2021
|
مواد مشابهة
-
Oligonucleotide-based therapies for neuromuscular disease
حسب: Douglas, A, وآخرون
منشور في: (2015) -
Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
حسب: Tsoumpra, MK, وآخرون
منشور في: (2019) -
Advances in oligonucleotide drug delivery
حسب: Roberts, TC, وآخرون
منشور في: (2020) -
Recent advances in antisense oligonucleotide therapy in genetic neuromuscular diseases
حسب: Ashok Verma
منشور في: (2018-01-01) -
Cell-penetrating peptide conjugates of steric blocking oligonucleotides as therapeutics for neuromuscular diseases from a historical perspective to current prospects of treatment
حسب: Gait, M, وآخرون
منشور في: (2018)